These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
313 related items for PubMed ID: 20930301
1. The effect of MAPT H1 and APOE ε4 on transition from mild cognitive impairment to dementia. Samaranch L, Cervantes S, Barabash A, Alonso A, Cabranes JA, Lamet I, Ancín I, Lorenzo E, Martínez-Lage P, Marcos A, Clarimón J, Alcolea D, Lleó A, Blesa R, Gómez-Isla T, Pastor P. J Alzheimers Dis; 2010; 22(4):1065-71. PubMed ID: 20930301 [Abstract] [Full Text] [Related]
2. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttilä T. Neurobiol Aging; 2007 Apr; 28(4):507-14. PubMed ID: 16546302 [Abstract] [Full Text] [Related]
3. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A, Darreh-Shori T, Soininen H, Pirttilä T, Farlow MR, Sfikas N, Ballard C, Greig NH. Pharmacogenet Genomics; 2008 Apr; 18(4):289-98. PubMed ID: 18334913 [Abstract] [Full Text] [Related]
4. ApoE alleles and tau markers in patients with different levels of cognitive impairment. Lavados M, Farías G, Rothhammer F, Guillon M, Mujica MC, Maccioni C, Maccioni RB. Arch Med Res; 2005 Apr; 36(5):474-9. PubMed ID: 16099324 [Abstract] [Full Text] [Related]
5. Apolipoprotein E epsilon 4 allele is associated with increased atrophy in progressive mild cognitive impairment: a voxel-based morphometric study. Hämäläinen A, Grau-Olivares M, Tervo S, Niskanen E, Pennanen C, Huuskonen J, Kivipelto M, Hänninen T, Tapiola M, Vanhanen M, Hallikainen M, Helkala EL, Nissinen A, Vanninen RL, Soininen H. Neurodegener Dis; 2008 Apr; 5(3-4):186-9. PubMed ID: 18322386 [Abstract] [Full Text] [Related]
6. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele. Smach MA, Charfeddine B, Lammouchi T, Harrabi I, Ben Othman L, Dridi H, Bennamou S, Limem K. Neurosci Lett; 2008 Aug 01; 440(2):145-9. PubMed ID: 18555606 [Abstract] [Full Text] [Related]
7. Selective brain gray matter atrophy associated with APOE ε4 and MAPT H1 in subjects with mild cognitive impairment. Goñi J, Cervantes S, Arrondo G, Lamet I, Pastor P, Pastor MA. J Alzheimers Dis; 2013 Aug 01; 33(4):1009-19. PubMed ID: 23064258 [Abstract] [Full Text] [Related]
8. Mortality in amnestic mild cognitive impairment: a prospective community study. Hunderfund AL, Roberts RO, Slusser TC, Leibson CL, Geda YE, Ivnik RJ, Tangalos EG, Petersen RC. Neurology; 2006 Nov 28; 67(10):1764-8. PubMed ID: 17130407 [Abstract] [Full Text] [Related]
9. [Dementia and cognitive impairment pattern: its association with epsilon4 allele of apolipoprotein E gene]. Rosich-Estragó M, Figuera-Terré L, Mulet-Pérez B, Arrufat-Cardús MT, Pascual San Emeterio A, Arbeola-Rigau I, Labad-Alquézar A, Vilella-Cuadrada E. Rev Neurol; 2006 Nov 28; 38(9):801-7. PubMed ID: 15152345 [Abstract] [Full Text] [Related]
10. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM. Biol Psychiatry; 2004 Nov 01; 56(9):670-6. PubMed ID: 15522251 [Abstract] [Full Text] [Related]
11. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Goodkind M, Scarmeas N, Braun I, Stern Y, Mayeux R. Arch Neurol; 2005 Jun 01; 62(6):975-80. PubMed ID: 15956169 [Abstract] [Full Text] [Related]
13. Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Caselli RJ, Reiman EM, Locke DE, Hutton ML, Hentz JG, Hoffman-Snyder C, Woodruff BK, Alexander GE, Osborne D. Arch Neurol; 2007 Sep 01; 64(9):1306-11. PubMed ID: 17846270 [Abstract] [Full Text] [Related]
14. Apolipoprotein epsilon4 and neuropsychological performance in Alzheimer's disease and vascular dementia. McGuinness B, Carson R, Barrett SL, Craig D, Passmore AP. Neurosci Lett; 2010 Oct 08; 483(1):62-6. PubMed ID: 20678545 [Abstract] [Full Text] [Related]
15. Effect of APOE ε4 allele on cortical thicknesses and volumes: the AddNeuroMed study. Liu Y, Paajanen T, Westman E, Wahlund LO, Simmons A, Tunnard C, Sobow T, Proitsi P, Powell J, Mecocci P, Tsolaki M, Vellas B, Muehlboeck S, Evans A, Spenger C, Lovestone S, Soininen H, AddNeuroMed Consortium. J Alzheimers Dis; 2010 Oct 08; 21(3):947-66. PubMed ID: 20693633 [Abstract] [Full Text] [Related]
16. The association between delirium and the apolipoprotein E epsilon4 allele in the elderly. van Munster BC, Korevaar JC, de Rooij SE, Levi M, Zwinderman AH. Psychiatr Genet; 2007 Oct 08; 17(5):261-6. PubMed ID: 17728664 [Abstract] [Full Text] [Related]
18. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Smith EE, Egorova S, Blacker D, Killiany RJ, Muzikansky A, Dickerson BC, Tanzi RE, Albert MS, Greenberg SM, Guttmann CR. Arch Neurol; 2008 Jan 08; 65(1):94-100. PubMed ID: 18195145 [Abstract] [Full Text] [Related]
19. Effect of MAPT and APOE on prognosis of progressive supranuclear palsy. Baba Y, Putzke JD, Tsuboi Y, Josephs KA, Thomas N, Wszolek ZK, Dickson DW. Neurosci Lett; 2006 Sep 11; 405(1-2):116-9. PubMed ID: 16839689 [Abstract] [Full Text] [Related]
20. The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment. Aggarwal NT, Wilson RS, Beck TL, Bienias JL, Berry-Kravis E, Bennett DA. Neurocase; 2005 Feb 11; 11(1):3-7. PubMed ID: 15804918 [Abstract] [Full Text] [Related] Page: [Next] [New Search]